[go: up one dir, main page]

WO2006125962A3 - T cell receptors which specifically bind to vygfvracl-hla-a24 - Google Patents

T cell receptors which specifically bind to vygfvracl-hla-a24 Download PDF

Info

Publication number
WO2006125962A3
WO2006125962A3 PCT/GB2006/001857 GB2006001857W WO2006125962A3 WO 2006125962 A3 WO2006125962 A3 WO 2006125962A3 GB 2006001857 W GB2006001857 W GB 2006001857W WO 2006125962 A3 WO2006125962 A3 WO 2006125962A3
Authority
WO
WIPO (PCT)
Prior art keywords
vygfvracl
hla
cell receptors
specifically bind
tcrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/001857
Other languages
French (fr)
Other versions
WO2006125962A2 (en
Inventor
Bent Karsten Jakobsen
Yi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/002078 external-priority patent/WO2005116646A1/en
Priority claimed from GBGB0524477.7A external-priority patent/GB0524477D0/en
Priority to JP2008512901A priority Critical patent/JP5149789B2/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Priority to EP06727144A priority patent/EP1885754B1/en
Priority to AT06727144T priority patent/ATE497976T1/en
Priority to US11/915,190 priority patent/US8017730B2/en
Priority to CN2006800182554A priority patent/CN101389652B/en
Priority to DE602006020037T priority patent/DE602006020037D1/en
Publication of WO2006125962A2 publication Critical patent/WO2006125962A2/en
Publication of WO2006125962A3 publication Critical patent/WO2006125962A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting tha complex.
PCT/GB2006/001857 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24 Ceased WO2006125962A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE602006020037T DE602006020037D1 (en) 2005-05-25 2006-05-19 Specifically to VYGFVRACL-HLA-A24 Binding T-cell Receptors
CN2006800182554A CN101389652B (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to VYGFVRACL-HLA-A24
JP2008512901A JP5149789B2 (en) 2005-05-25 2006-05-19 T cell receptor that specifically binds to VYGFVRACL-HLA-A24
EP06727144A EP1885754B1 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24
AT06727144T ATE497976T1 (en) 2005-05-25 2006-05-19 T CELL RECEPTORS BINDING SPECIFICALLY TO VYGFVRACL-HLA-A24
US11/915,190 US8017730B2 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to VYGFVRACL-HLA-A24

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBPCT/GB2005/002078 2005-05-25
PCT/GB2005/002078 WO2005116646A1 (en) 2004-05-26 2005-05-25 Method for the identification of a polypeptide which binds to a given pmhc complex
GBGB0524477.7A GB0524477D0 (en) 2005-11-30 2005-11-30 Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0524477.7 2005-11-30

Publications (2)

Publication Number Publication Date
WO2006125962A2 WO2006125962A2 (en) 2006-11-30
WO2006125962A3 true WO2006125962A3 (en) 2007-02-01

Family

ID=37395870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001857 Ceased WO2006125962A2 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24

Country Status (2)

Country Link
EP (1) EP1885754B1 (en)
WO (1) WO2006125962A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11183272B2 (en) 2018-12-21 2021-11-23 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11650211B2 (en) 2017-02-12 2023-05-16 Biontech Us Inc. HLA-based methods and compositions and uses thereof

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
KR101803099B1 (en) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 Antibodies and processes for preparing the same
ES2681478T3 (en) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. MYC modulators, methods of use thereof and methods to identify agents that modulate MYC
EP2877189B1 (en) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
CR20200476A (en) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc Shared neoantigens
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
EP4242298A2 (en) 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHODS TARGETING COMPONENT 3 OF THE COMPLEMENT TO INHIBIT TUMOR GROWTH
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
SG11202000612TA (en) 2017-08-03 2020-02-27 Taiga Biotechnologies Inc Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR102338449B1 (en) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 Systems, methods, and compositions for targeted nucleic acid editing
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology Calling genetic variation from single-cell transcriptomes
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
WO2019195586A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusion with CD8 antigen binding molecules to modulate immune cell function
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044004A2 (en) * 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
WO2005116075A1 (en) * 2004-05-26 2005-12-08 Avidex Ltd. High affinity telomerase t cell receptors
WO2006064176A1 (en) * 2004-12-16 2006-06-22 Avidex Ltd Assays for superantigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044004A2 (en) * 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
WO2005116075A1 (en) * 2004-05-26 2005-12-08 Avidex Ltd. High affinity telomerase t cell receptors
WO2006064176A1 (en) * 2004-12-16 2006-06-22 Avidex Ltd Assays for superantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAI JUNKO ET AL: "Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes", BLOOD, vol. 97, no. 9, 1 May 2001 (2001-05-01), pages 2903 - 2907, XP002408551, ISSN: 0006-4971 *
COLE DAVID K ET AL: "Crystal structure of HLA-A*2402 complexed with a telomerase peptide", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 36, no. 1, January 2006 (2006-01-01), pages 170 - 179, XP002408552, ISSN: 0014-2980 *
LI YI ET AL: "Directed evolution of human T-cell receptors with picomolar affinities by phage display", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 3, March 2005 (2005-03-01), pages 349 - 354, XP002336795, ISSN: 1087-0156 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11650211B2 (en) 2017-02-12 2023-05-16 Biontech Us Inc. HLA-based methods and compositions and uses thereof
US11183272B2 (en) 2018-12-21 2021-11-23 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells

Also Published As

Publication number Publication date
EP1885754B1 (en) 2011-02-09
WO2006125962A2 (en) 2006-11-30
EP1885754A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2009070243A3 (en) Wise binding antibodies and epitopes
MA32190B1 (en) Antibodies to angiopoietin 1 and angiopoietin 2 and their use
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP2175884B8 (en) Combination therapies employing gitr binding molecules
WO2008157356A3 (en) Antibody formulations
WO2008089397A3 (en) Adrb2 cancer markers
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2009113828A3 (en) Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2008010162A3 (en) Intracellular targeting of molecules
MX2010007716A (en) COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART.
WO2009055074A3 (en) Erbb2 binding proteins and use thereof
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma
AU2006239318A8 (en) Cancer specific PCNA isoform binding antibodies and uses thereof
EP1975184A3 (en) Serine or threonine phosphorylation sites
WO2008036337A8 (en) Predicted phosphorylation sites
WO2007041397A3 (en) Targeted pharmaceuticals and ligands
WO2006117193A3 (en) Receptor in dendritic cells
WO2009009613A3 (en) Novel ion channel-forming peptides
AU2012261508A1 (en) Wise binding antibodies and epitopes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680018255.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008512901

Country of ref document: JP

Ref document number: 2006727144

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727144

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006727144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11915190

Country of ref document: US